ClinicalTrials.gg
RecruitingNCT06766916CRYSTALUpdated May 18, 2025

Crisugabalin for Radiotherapy-Related Neuropathic Pain

A Phase 2 interventional study of Crisugabalin and Pregabalin in Neuropathic Pain, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Neuralgia with a site in China — 17 open to participants now, 17 under way, 1 of them phase 3. Neuralgia · China.

Planned enrollment
14th of 31
172 · median 147
Started
2025
with 6 others
Phase 2
9 of 41
4 open now
Primary completion
2026-11
later than 10 of 16 live
Registered
28th of 41
by date
Lead sponsor
3 of 41
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Among the 41 studies in Neuralgia with a site in China, this one is the 14th largest by planned enrollment of the 31 interventional ones that give a count, is one of 7 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 10 of the 16 other live ones, and was the 28th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

17 of the 41 studies in Neuralgia with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Neuralgia with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether Crisugabalin has similar efficacy compared to Pregabalin in reducing radiotherapy-related neuropathic pain (RRNP) in patients with head and neck cancers.

Read the detailed description

The primary objective of this study is to determine whether Crisugabalin provides non-inferior pain relief compared to Pregabalin in patients with head and neck cancer experiencing radiotherapy-related neuropathic pain. The trial adopts a multicenter, randomized, open-label design, and the primary endpoint is the change in Numeric Rating Scale (NRS) pain scores from baseline to 4 weeks. The study aims to provide new evidence to support treatment strategies for this condition, which significantly affects patients' quality of life.

03

Conditions studied

  • Neuropathic Pain

Keywords

  • Head and Neck Cancers
  • Radiotherapy-Related Neuropathic Pain
  • Crisugabalin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and voluntarily sign a written form.
  2. Male or female patients aged ≥18 years with an expected survival of at least 5 months.
  3. confirmed head and neck tumors treated with radiotherapy at least 6 months prior to screening.
  4. Average NRS pain score ≥4 over 7 days during the screening period, with pain localized to nerve-innervated areas corresponding to the radiotherapy site, such as the head, face, neck, and arms.
  5. Diagnosis of neuropathic pain persisting for at least 4 weeks, confirmed by two trained neurologists based on clinical history, symptoms, signs, and a Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) score ≥12 (Chinese version).
  6. Adequate cognitive and language abilities to communicate and complete study questionnaires.

Exclusion criteria

Exclusion Criteria:

  1. Severe abnormalities in hematological, hepatic, or renal function, as evidenced by:

    • Hematology: \<1.5×10⁹/L, count \<90×10⁹/L, or \<100 g/L.
    • Liver function: (ALT) or aspartate aminotransferase (AST) >3× (ULN), or total (TBIL) >1.5× ULN.
    • Renal function: Estimated (eGFR) \<60 mL/min/1.73 m² or undergoing dialysis.
    • Creatine kinase >2× ULN.
  2. Chronic systemic diseases that may interfere with study participation, including but not limited to:

    • Severe cardiopulmonary diseases such as unstable angina, myocardial infarction, severe arrhythmia, WHO functional classification III-IV heart failure, uncontrolled hypertension (systolic BP >160 mmHg or diastolic BP >100 mmHg), or recurrent asthma.
    • Chronic gastrointestinal diseases, such as liver fibrosis, recurrent indigestion or diarrhea, or peptic ulcers.
    • Neurological or psychiatric conditions affecting pain assessment, including epilepsy, recurrent dizziness, headache, memory, or cognitive disorders; cerebrovascular accidents or within 6 months of screening.
  3. Known allergy to study drugs or chemically related compounds.
  4. Current diagnosis of tumor recurrence or associated with tumor-related pain.
  5. Neuropathic pain not caused by radiotherapy, such as postherpetic neuralgia, diabetic neuropathy, -related neuropathy, spinal cord injury, or other neurological diseases.
  6. Use of pregabalin/crisugabalin within 4 weeks before screening.
  7. Pregnant, planning to become pregnant during the study, or breastfeeding. Participants and their partners unwilling to use reliable (e.g., condoms, spermicides, intrauterine devices) from the time of consent until 28 days after the last dose of study medication.
  8. Participation in any other clinical trial within 30 days prior to screening.
  9. Any other condition deemed unsuitable for study participation by the investigator.
  10. Use of prohibited medications within at least 5 half-lives of the drug before screening, with prohibition maintained throughout the study.
  11. Previous use of pregabalin ≥300 mg/day or gabapentin ≥1200 mg/day deemed ineffective.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (estimated)

Study arms

  • Experimental
    Crisugabalin

    The initial dose is one Crisugabalin capsule (20 mg) taken twice daily. The dose will be gradually increased to the maximum tolerated dose or the maximum daily dose of three capsules (60 mg) taken twice daily.

    Drug: Crisugabalin

  • Active comparator
    Pregabalin

    The initial dose is one capsule of Pregabalin (75 mg) taken twice daily. The dose will be gradually increased to the maximum tolerated dose or the maximum daily dose of four capsules (300 mg) taken twice daily.

    Drug: Pregabalin

Interventions

  • Days 1-14: Crisugabalin 40 mg/day, 20 mg twice daily, orally. Days 15-21: Increase dose to 80 mg/day, 40 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period. Days 22-28: Increase dose to 120 mg/day, 60 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.

  • Days 1-7: Pregabalin 150 mg/day, 75 mg twice daily, orally. Days 8-14: Increase dose to 300 mg/day, 150 mg twice daily. Days 15-21: Increase dose to 450 mg/day, 225 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period. Days 22-28: Increase dose to 600 mg/day, 300 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.

06

What researchers measure

Primary outcomes

  1. Numeric Rating Scale (NRS) Change

    The change in NRS score from baseline to Week 4 of treatment. The NRS measures pain intensity on a scale of 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.

    Time frame: 4 weeks

Secondary outcomes

  1. Numeric Rating Scale (NRS) Change

    The change in NRS score from baseline to Week 1 of treatment. The NRS measures pain intensity on a scale of 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.

    Time frame: 1 week

  2. Visual Analogue Scale (VAS) Change

    The VAS measures pain intensity on a 0-100 mm scale, with 0 representing no pain and 100 representing the worst imaginable pain.

    Time frame: 4 weeks

  3. Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) scores

    The HAMA and HAMD are used to evaluate anxiety and depressive symptoms, respectively.

    Time frame: 4 weeks

  4. Daily Sleep Interference Scale (DSIS)

    The DSIS measures the impact of pain on sleep quality. Scores range from 0 (no interference) to 10 (complete interference).

    Time frame: 4 weeks

  5. Health Status According to EuroQol-5-Domain-5-Level health questionnaire (EQ-5D-5L)

    The EQ-5D-5L assessed quality of life based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant was asked to 'check the ONE box that best describes your health TODAY,' choosing from 5 options (no problems, slight problems, moderate problems, severe problems, extreme problems) provided under each dimension. The health state index value is a single value on a scale from 0 to 100 scores indicating better health: 0 = indicating worst health and 100 = best imaginable health.

    Time frame: 4 weeks

  6. Response Rates

    The proportion of patients achieving ≥30% and ≥50% reductions in NRS score from baseline to Week 4.

    Time frame: 4 weeks

  7. Short-Form McGill Pain Questionnaire (SF-MPQ)

    Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score: Part 1 - fifteen descriptors of pain intensity, on a scale of 0 (none) to 3 (severe); Part 2 - the VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain; Part 3 - a present pain intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain).

    Time frame: 4 weeks

  8. Patient Global Impression of Change (PGIC)

    PGIC is a 7 point scale depicting a patient's rating of overall improvement, with 1 representing very much improved and 7 representing very much worse.

    Time frame: 4 weeks

07

Study locations

1 of 11 sites recruiting
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Not yet recruiting
    • Jingfeng Zong · Contactzongjingfeng@126.com · 86+13365910013
    • Jingfeng Zong · Principal investigator
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510000, China
    Recruiting
    • Songhua Xiao · Contactxiaosh@mail.sysu.edu.cn · 86+13922232774
    • Songhua Xiao · Sub investigator
    • Yamei Tang · Principal investigator
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Not yet recruiting
    • Haiqiang Mai · Contactmaihq@sysucc.org.cn · 86+135 7002 7338
    • Haiqiang Mai · Principal investigator
    • Liting Liu · Sub investigator
  • Affillated Cancer Hospital and Institute of Guangzhou Medical University
    Guangzhou, Guangdong 510095, China
    Not yet recruiting
    • Dongping Chen · Contactchen_dpgz@163.com · 86+13302215492
    • Bin Qi · Sub investigator
    • Dongping Chen · Principal investigator
  • The Affiliated Brain Hospital, Guangzhou Medical University
    Guangzhou, Guangdong 510370, China
    Not yet recruiting
  • Zhongshan People's Hospital
    Zhongshan, Guangdong 528403, China
    Not yet recruiting
    • Kui Lu · Contactlukui945@163.com · 86+18028389017
    • Kui Lu · Principal investigator
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 510120, China
    Not yet recruiting
    • Yuan Wu · Contactwuyuan90@126.com · 86+136 0771 3316
    • Yuan Wu · Principal investigator
  • Henan Cancer Hospital (Affiliated Cancer Hospital of ZhengzhouUniversity)
    Zhengzhou, Henan 450003, China
    Not yet recruiting
    • Guanglun Xie · Contactxieguanglun@126.com · 86+139 3902 9792
    • Guanglun Xie · Principal investigator
  • Hunan Provincial People's Hospital
    Changsha, Hunan 410005, China
    Not yet recruiting
    • Huaxin Duan · Contact317102912@qq.com · 86+13347315509
    • Huaxin Duan · Principal investigator
  • Hunan Brain Hospital
    Changsha, Hunan 410007, China
    Not yet recruiting
    • Nong Yang · Contact13055193557@qq.com · 86+13055193557
    • Nong Yang · Principal investigator
  • Changsha Central Hospital
    Changsha, Hunan 41004, China
    Not yet recruiting
    • Guihua Wang · Contact18874186878@qq.com · 86+18874186878
    • Guihua Wang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — The IPD will be available from Principal Investigator upon reasonable request 6 months after the trial completion.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 6 months after the trial completion

Access criteria: The IPD will be available from Principal Investigator upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.

Of 58 phase 2 interventional studies under Neuralgia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2025
First posted
Jan 9, 2025
StartActual
May 7, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06766916
Responsible party
Yamei Tang (Professor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Jan 9, 2025
Start date
May 7, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 18, 2025

Study contacts

Songhua Xiao
Contact
xiaosh@mail.sysu.edu.cn
86+13922232774
Yamei Tang, M.D., PhD
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crisugabalin

Start the discussion